| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Pseudolaric acid B β-D-glucoside targets cellular pathways involved in cytotoxicity and antifungal activity. As a diterpenoid glycoside, it is believed to exert its biological effects through interactions with cellular membranes and signaling pathways. Its anti-tumor and anti-inflammatory activities suggest modulation of pathways critical for cell survival and inflammation.
|
|---|---|
| ln Vitro |
In vitro, Pseudolaric acid B β-D-glucoside exhibits various biological activities, including cytotoxic, antifungal, anti-inflammatory, and anti-tumor properties. Its activity is assessed using cell-based assays measuring cell viability, fungal growth inhibition, and inflammatory marker expression.
|
| ln Vivo |
In vivo activity data for Pseudolaric acid B β-D-glucoside are limited in the available literature. As a natural product research compound, its primary application is in in vitro studies. Its anti-tumor and anti-inflammatory properties suggest potential for in vivo applications, but systematic in vivo studies are lacking.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Pseudolaric acid B β-D-glucoside are not extensively documented. As a natural product, its biological activity is typically assessed in cell-based assays rather than cell-free enzyme assays. Its cytotoxic and antifungal activities are evaluated using standard viability and growth inhibition assays.
|
| Cell Assay |
In vitro cellular assays for Pseudolaric acid B β-D-glucoside are performed using various cell lines, such as cancer cells or fungal cultures. Cells are treated with the compound, and cell viability is assessed using MTT or other cytotoxicity assays. Antifungal activity is evaluated by measuring inhibition of fungal growth. Anti-inflammatory activity is assessed by measuring the production of inflammatory cytokines in immune cells.
|
| Animal Protocol |
In vivo animal experiments for Pseudolaric acid B β-D-glucoside are not extensively documented. As a research compound, in vivo studies would typically involve administration to animal models of cancer or inflammation. The compound would be administered via appropriate routes, and efficacy would be assessed by measuring tumor growth, inflammation markers, or infection clearance.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Pseudolaric acid B β-D-glucoside have not been systematically characterized. The compound has a molecular weight of 594.60, molecular formula C29H38O13, and a purity of >98%. It is a glycoside derived from the bark of Pseudolarix amabilis. Further PK studies are needed.
|
| Toxicity/Toxicokinetics |
Toxicological data for Pseudolaric acid B β-D-glucoside are not extensively reported. As a research-use natural product, its safety profile has not been formally evaluated in comprehensive toxicology studies. The compound is intended for research purposes only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Reports indicate that pseudolarix amabilis and Larix kaempferi have been found to contain BO-β-D-glucopyranoside, and relevant data are available for reference.
Pseudolaric acid B β-D-glucoside is also known as Pseudolaric Acid B O-β-D-Glucopyranoside. It is a diterpenoid isolated from Pseudolarix kaempferi (golden larch) and exhibits cytotoxic, antifungal, anti-inflammatory, and anti-tumor properties. This product is for research use only. |
| Molecular Formula |
C29H38O13
|
|---|---|
| Molecular Weight |
594.6042
|
| Exact Mass |
594.231
|
| CAS # |
98891-41-9
|
| PubChem CID |
10031398
|
| Appearance |
White to off-white solid powder
|
| Density |
1.42±0.1 g/cm3 (20 ºC 760 Torr)
|
| Boiling Point |
766.5±60.0℃ at 760 mmHg
|
| LogP |
0.129
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
42
|
| Complexity |
1210
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C/C(=C\C=C\[C@@]1([C@@H]2CC[C@@]3([C@@]2(CCC(=CC3)C(=O)OC)OC(=O)C)C(=O)O1)C)/C(=O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O
|
| InChi Key |
UUDZDKPKXAEKLA-YHLOYHKPSA-N
|
| InChi Code |
InChI=1S/C29H38O13/c1-15(23(35)40-25-22(34)21(33)20(32)18(14-30)39-25)6-5-10-27(3)19-9-12-28(26(37)42-27)11-7-17(24(36)38-4)8-13-29(19,28)41-16(2)31/h5-7,10,18-22,25,30,32-34H,8-9,11-14H2,1-4H3/b10-5+,15-6+/t18-,19+,20-,21+,22-,25+,27-,28-,29+/m1/s1
|
| Chemical Name |
methyl (1R,7S,8S,9R)-7-acetyloxy-9-methyl-9-[(1E,3E)-4-methyl-5-oxo-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypenta-1,3-dienyl]-11-oxo-10-oxatricyclo[6.3.2.01,7]tridec-3-ene-4-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~168.18 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.20 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.20 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.20 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6818 mL | 8.4090 mL | 16.8180 mL | |
| 5 mM | 0.3364 mL | 1.6818 mL | 3.3636 mL | |
| 10 mM | 0.1682 mL | 0.8409 mL | 1.6818 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
